A 72-year-old man with a history of hypertension and diabetes presents with progressive bone pain in the lumbar spine and pelvis for 3 months. PSA is 85 ng/mL. MRI spine shows multiple lytic and sclerotic lesions in the lumbar vertebrae and pelvis. Bone scan confirms widespread skeletal metastases. Serum alkaline phosphatase is elevated at 95 U/L. A bone biopsy confirms metastatic adenocarcinoma of prostate origin. The patient is asymptomatic from urinary obstruction. What is the most appropriate initial hormonal therapy?

Explanation

## Disease Stage & Hormone-Sensitivity Assessment This patient has **metastatic hormone-sensitive prostate cancer (mHSPC)**: - Very high PSA (85 ng/mL) - Widespread bone metastases (M1b) - No prior hormonal therapy (treatment-naïve) - Good performance status (asymptomatic from urinary obstruction) **Key Point:** Metastatic prostate cancer is presumed hormone-sensitive until proven otherwise. First-line treatment is **androgen deprivation therapy (ADT)** combined with a second-generation androgen receptor antagonist. ## Landmark Evidence: CHAARTED & LATITUDE Trials | Trial | Population | Intervention | Primary Outcome | Benefit | |-------|-----------|--------------|-----------------|----------| | **CHAARTED** | mHSPC, treatment-naïve | Docetaxel + ADT vs ADT alone | OS at 28 months | +13.6 months OS (HR 0.61) | | **LATITUDE** | mHSPC, high-risk | Abiraterone + prednisone + ADT vs ADT alone | OS at 30 months | +16.8 months OS (HR 0.53) | | **ENZAMET** | mHSPC, treatment-naïve | Enzalutamide + ADT vs ADT alone | OS at 34 months | +10.7 months OS (HR 0.67) | **High-Yield:** For newly diagnosed mHSPC, ADT (GnRH agonist ± antagonist) PLUS a second-generation agent (abiraterone, enzalutamide, or docetaxel) is superior to ADT monotherapy. [cite:NCCN Prostate Cancer Guidelines 2023] ## Why Combination ADT (GnRH Agonist + Bicalutamide)? 1. **GnRH agonist (leuprolide, goserelin, triptorelin):** - Suppresses testicular testosterone production (LH-dependent). - Achieves castrate levels of testosterone (<50 ng/dL) in 2–4 weeks. - Requires antiandrogen "flare" cover (bicalutamide 50 mg × 7 days) to prevent initial surge. 2. **Androgen receptor antagonist (bicalutamide 50 mg daily):** - Blocks residual adrenal androgens and intracrine androgen synthesis. - At 50 mg (not 150 mg), provides additive benefit without increased toxicity. - 150 mg monotherapy is inferior to combination therapy. **Clinical Pearl:** "Maximum androgen blockade" (GnRH agonist + 50 mg bicalutamide) achieves ~95% suppression of androgen signaling and is the foundation of ADT. ## Why NOT the Other Options? **Bicalutamide 150 mg monotherapy:** - Historically used as monotherapy in older men, but inferior to combination ADT. - Does NOT suppress testicular testosterone adequately. - Contraindicated as first-line in this fit, younger-elderly patient with mHSPC. **Abiraterone + prednisone:** - Second-generation CYP17 inhibitor; excellent in CRPC (castration-resistant) and high-volume mHSPC. - LATITUDE trial showed benefit in high-risk mHSPC, but requires GnRH agonist as backbone. - Typically reserved for CRPC or as intensification in high-volume disease. - More expensive; not standard first-line monotherapy. **Enzalutamide monotherapy:** - Potent AR antagonist; superior to bicalutamide in CRPC. - ENZAMET trial used enzalutamide + ADT (not monotherapy). - Monotherapy is NOT guideline-recommended for mHSPC. ## Recommended Approach ```mermaid flowchart TD A[mHSPC, treatment-naïve]:::outcome --> B[GnRH agonist + Bicalutamide 50 mg]:::action B --> C{High-volume disease<br/>or rapid progression?}:::decision C -->|Yes| D[Add docetaxel or abiraterone]:::action C -->|No| E[Monitor PSA, testosterone,<br/>clinical response]:::action E --> F{PSA decline >50%<br/>at 3 months?}:::decision F -->|Yes| G[Continue ADT monotherapy]:::action F -->|No| H[Consider early intensification]:::action ``` **Mnemonic:** **"GLAD"** — **G**nRH agonist + **L**ow-dose bicalutamide (50 mg) = **A**ndrogen **D**eprivation (foundation of mHSPC therapy).